Get the Stockscreener App
3.65
0.00%
0.00
After Hours:
3.54
-0.11
-3.01%
Editas Medicine Inc stock is traded at $3.65, with a volume of 2.95M.
It is up +0.00% in the last 24 hours and up +34.69% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
See More
Previous Close:
$3.65
Open:
$3.6
24h Volume:
2.95M
Relative Volume:
1.28
Market Cap:
$560.14M
Revenue:
$38.69M
Net Income/Loss:
$-108.95M
P/E Ratio:
-2.9857
EPS:
-1.2225
Net Cash Flow:
$-141.09M
1W Performance:
+14.06%
1M Performance:
+34.69%
6M Performance:
+70.56%
1Y Performance:
+42.02%
1-Day Range:
$3.55
$3.79
1-Week Range:
$3.11
$3.79
52-Week Range:
$1.66
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.65 | 497.22M | 38.69M | -108.95M | -141.09M | -1.2225 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Editas Medicine, Inc.(NasdaqGS:EDIT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2500 Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2000 Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 3000E Growth Benchmark - marketscreener.com
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Price to sales forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Price to earnings forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Enterprise value to EBITDA forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Price to earnings forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Enterprise value to revenue forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Price to book forward of Editas Medicine, Inc. – NASDAQ:EDIT - TradingView
Editas Medicine, Inc. Actuals & Estimates (NASDAQ:EDIT) - TradingView
Enterprise value to EBITDA forward of Editas Medicine, Inc. – LSE:0IFK - TradingView
Editas Medicine, Inc. Actuals & Estimates (LSE:0IFK) - TradingView
EDIT Forecast — Price Target — Prediction for 2027 - TradingView
Editas Medicine, Inc. Actuals & Estimates (FWB:8EM) - TradingView
Editas Medicine Inc (EDIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Editas Medicine, Inc. Actuals & Estimates (BOATS:EDIT) - TradingView
8EM Forecast — Price Target — Prediction for 2027 - TradingView
Editas Medicine Inc (EDIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hirsch Andrew - Moomoo
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Scadden David - Moomoo
Editas Medicine Inc (EDIT) Institutional Confidence - TradingKey
Form 4 Editas Medicine For: 22 June By Investing.com - Investing.com South Africa
[Form 4] Editas Medicine, Inc. Insider Trading Activity - Stock Titan
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Connaughton Bernadette - Moomoo
Editas Medicine (NASDAQ: EDIT) director granted 51,700 stock options at $2.55 - Stock Titan
Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hopfield Jessica - Moomoo
Editas Medicine (EDIT) director Andrew Hirsch awarded 51,700 stock options - Stock Titan
Editas Medicine (EDIT) director awarded 51,700 stock options at $2.55 strike - Stock Titan
Editas Medicine (EDIT) director granted 51,700 stock options at $2.55 strike - Stock Titan
Editas Medicine elects two directors and ratifies auditor at annual meeting - Investing.com Canada
Editas Medicine elects two directors and ratifies auditor at annual meeting By Investing.com - Investing.com South Africa
Editas Medicine (NASDAQ: EDIT) stockholders elect directors and ratify PwC at 2026 meeting - Stock Titan
Editas Medicine Inc (EDIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Editas Medicine Inc (EDIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Editas Medicine Inc (EDIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Editas Medicine Inc (EDIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Editas Medicine Inc (EDIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Editas Medicine Inc (EDIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Editas Medicine Inc Annual Shareholders Meeting Transcript - GuruFocus
Editas Medicine Shares Slide 9.36%: Key Support Levels in FocusJelly Roll Trade - dars.gov.et
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock By Investing.com - Investing.com India
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc - GuruFocus
COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medici - GuruFocus
Editas Medicine CFO Amy Parison sells $1,253 in stock By Investing.com - Investing.com South Africa
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock - Investing.com
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Editas Medicine Inc Stock (EDIT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'Neill Gilmore Neil | CEO |
Jun 03 '26 |
Sale |
2.70 |
15,380 |
41,543 |
248,313 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Jun 03 '26 |
Sale |
2.70 |
731 |
1,975 |
67,297 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):